Published in AAPS J on March 04, 2015
Identification of Novel Inhibitors of Organic Anion Transporting Polypeptides 1B1 and 1B3 (OATP1B1 and OATP1B3) Using a Consensus Vote of Six Classification Models. Mol Pharm (2015) 0.82
Contribution of Organic Anion-Transporting Polypeptides 1A/1B to Doxorubicin Uptake and Clearance. Mol Pharmacol (2016) 0.75
The Importance of Steroid Uptake and Intracrine Action in Endometrial and Ovarian Cancers. Front Pharmacol (2017) 0.75
Heptamethine carbocyanine DZ-1 dye for near-infrared fluorescence imaging of hepatocellular carcinoma. Oncotarget (2017) 0.75
Effect of Liver Disease on Hepatic Transporter Expression and Function. J Pharm Sci (2017) 0.75
Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch (2003) 3.33
Impact of OATP transporters on pharmacokinetics. Br J Pharmacol (2009) 2.97
Visualization of hepatic uptake transporter function in healthy subjects by using gadoxetic acid-enhanced MR imaging. Radiology (2012) 2.90
Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther (2007) 2.52
Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology (2010) 2.48
Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology (2001) 2.36
Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther (2005) 2.23
Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol (2009) 2.23
A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol (2000) 2.21
Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol (2009) 2.20
Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica (2008) 2.18
Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol Pharmacol (2008) 2.11
LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology (2001) 2.02
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res (2008) 1.95
Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem (1999) 1.87
Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem (2000) 1.85
Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun (2000) 1.76
OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol (2012) 1.74
Altered expression of organic anion transporter polypeptide (OATP) genes in human breast carcinoma. Cancer Biol Ther (2008) 1.59
Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J Biol Chem (2005) 1.56
Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metab Dispos (2010) 1.53
Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev (2011) 1.51
Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol (2002) 1.49
Interaction of imatinib with human organic ion carriers. Clin Cancer Res (2008) 1.47
Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther (2000) 1.46
Prostaglandin transport. Prostaglandins Other Lipid Mediat (2002) 1.45
Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos (2004) 1.45
ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Res (2005) 1.42
The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Annu Rev Pharmacol Toxicol (2011) 1.41
Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther (2006) 1.38
Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. J Clin Invest (2010) 1.37
Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther (2003) 1.36
Expression of OATP family members in hormone-related cancers: potential markers of progression. PLoS One (2011) 1.32
Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther (2007) 1.28
Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics (2004) 1.28
Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A (2004) 1.27
Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. Cancer Res (2006) 1.26
Transporter gene expression in lactating and nonlactating human mammary epithelial cells using real-time reverse transcription-polymerase chain reaction. J Pharmacol Exp Ther (2002) 1.24
Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res (2012) 1.24
Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J Clin Invest (1996) 1.23
Characterization of organic anion transporting polypeptide 1b2-null mice: essential role in hepatic uptake/toxicity of phalloidin and microcystin-LR. Toxicol Sci (2008) 1.22
Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. Cancer Res (2008) 1.20
Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood (2012) 1.17
Regulation of prostaglandin transporters in colorectal neoplasia. Cancer Prev Res (Phila) (2008) 1.15
Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci (2008) 1.14
Potent cytotoxicity of the phosphatase inhibitor microcystin LR and microcystin analogues in OATP1B1- and OATP1B3-expressing HeLa cells. Mol Cancer Ther (2007) 1.14
Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther (2006) 1.11
Human liver-specific organic anion transporter-2 is a potent prognostic factor for human breast carcinoma. Cancer Sci (2007) 1.11
Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int (2005) 1.10
The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma. J Hepatol (2004) 1.09
Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients. Pharmacogenet Genomics (2006) 1.08
Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice. Clin Cancer Res (2012) 1.08
Detection of the human organic anion transporters SLC21A6 (OATP2) and SLC21A8 (OATP8) in liver and hepatocellular carcinoma. Lab Invest (2003) 1.07
Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1). Drug Metab Dispos (2008) 1.06
Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood (2013) 1.04
Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer. Cancer Res (2008) 1.04
Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps. Biochem Pharmacol (2006) 1.03
High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel. Clin Cancer Res (2010) 1.03
Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells. Mol Pharmacol (2002) 1.03
The role of STS and OATP-B mRNA expression in predicting the clinical outcome in human breast cancer. Anticancer Res (2007) 1.01
Identification of the gonad-specific anion transporter SLCO6A1 as a cancer/testis (CT) antigen expressed in human lung cancer. Cancer Immun (2004) 1.00
Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport. Biomed Pharmacother (2011) 0.99
Tumor-specific expression of organic anion-transporting polypeptides: transporters as novel targets for cancer therapy. J Drug Deliv (2013) 0.98
Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy. Cancer Chemother Pharmacol (2008) 0.96
Expression and localization of the uptake transporters OATP2B1, OATP3A1 and OATP5A1 in non-malignant and malignant breast tissue. Cancer Biol Ther (2011) 0.96
Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714. Toxicol Sci (2009) 0.96
Molecular determinants in the transport of a bile acid-derived diagnostic agent in tumoral and nontumoral cell lines of human liver. J Pharmacol Exp Ther (2006) 0.96
A cancer-specific variant of the SLCO1B3 gene encodes a novel human organic anion transporting polypeptide 1B3 (OATP1B3) localized mainly in the cytoplasm of colon and pancreatic cancer cells. Mol Pharm (2012) 0.95
Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett (2007) 0.95
Characterization of an organic anion-transporting polypeptide (OATP-B) in human placenta. J Clin Endocrinol Metab (2002) 0.94
Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors. Drug Metab Dispos (2009) 0.93
Diagnostic and pathogenetic implications of the expression of hepatic transporters in focal lesions occurring in normal liver. J Pathol (2005) 0.93
Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma. Hepatology (2014) 0.92
Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol (2003) 0.92
Organic anion transporting polypeptides expressed in pancreatic cancer may serve as potential diagnostic markers and therapeutic targets for early stage adenocarcinomas. Pharm Res (2013) 0.91
The analysis of organic anion transporting polypeptide (OATP) mRNA and protein patterns in primary and metastatic liver cancer. Cancer Biol Ther (2011) 0.91
Enhanced expression of organic anion transporting polypeptides (OATPs) in androgen receptor-positive prostate cancer cells: possible role of OATP1A2 in adaptive cell growth under androgen-depleted conditions. Biochem Pharmacol (2012) 0.91
Identification and characterization of novel rat and human gonad-specific organic anion transporters. Mol Endocrinol (2003) 0.91
Localization of organic anion transporting polypeptides in the rat and human ciliary body epithelium. Exp Eye Res (2005) 0.90
Identification of a new organic anion transporting polypeptide 1B3 mRNA isoform primarily expressed in human cancerous tissues and cells. Biochem Biophys Res Commun (2012) 0.88
Different expression patterns of organic anion transporting polypeptides in osteosarcomas, bone metastases and aneurysmal bone cysts. Oncol Rep (2009) 0.88
Differential role of organic anion-transporting polypeptides in estrone-3-sulphate uptake by breast epithelial cells and breast cancer cells. J Pharmacol Exp Ther (2012) 0.88
DNA methylation profiles of organic anion transporting polypeptide 1B3 in cancer cell lines. Pharm Res (2010) 0.87
Organic anion-transporting polypeptides: a novel approach for cancer therapy. J Drug Target (2013) 0.86
Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia. Clin Pharmacol Ther (2011) 0.86
Organic anion transporting polypeptide 1B3 (OATP1B3) is overexpressed in colorectal tumors and is a predictor of clinical outcome. Clin Exp Gastroenterol (2008) 0.85
Utility of a novel Oatp1b2 knockout mouse model for evaluating the role of Oatp1b2 in the hepatic uptake of model compounds. Drug Metab Dispos (2008) 0.85
Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for SN-38, an active metabolite of irinotecan, in humans. Pharm Res (2013) 0.85
Role of hypoxia inducible factor-1α in the regulation of the cancer-specific variant of organic anion transporting polypeptide 1B3 (OATP1B3), in colon and pancreatic cancer. Biochem Pharmacol (2013) 0.84
Epigenetic regulation of organic anion transporting polypeptide 1B3 in cancer cell lines. Pharm Res (2013) 0.83
Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters. Xenobiotica (2011) 0.83
Selectivity and potency of microcystin congeners against OATP1B1 and OATP1B3 expressing cancer cells. PLoS One (2014) 0.82
Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. Clin Pharmacol Ther (2010) 0.82
Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel. Int J Cancer (2014) 0.82
Organic Anion Transporting Polypeptide 5A1 (OATP5A1) in Small Cell Lung Cancer (SCLC) Cells: Possible Involvement in Chemoresistance to Satraplatin. Biomark Cancer (2011) 0.81
Estrone-3-sulphate, a potential novel ligand for targeting breast cancers. PLoS One (2013) 0.80
Expression of organic anion-transporting polypeptide 1A2 and organic cation transporter 6 as a predictor of pathologic response to neoadjuvant chemotherapy in triple negative breast cancer. Breast Cancer Res Treat (2014) 0.79
In vivo disposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transporters. Int J Cancer (2014) 0.79
Uptake transporter organic anion transporting polypeptide 1B3 contributes to the growth of estrogen-dependent breast cancer. J Steroid Biochem Mol Biol (2010) 0.78
Transporter function and cyclic AMP turnover in normal colonic mucosa from patients with and without colorectal neoplasia. BMC Gastroenterol (2012) 0.78
Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2013) 3.03
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol (2007) 2.51
Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology (2006) 2.43
Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw (2011) 2.03
The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med (2003) 1.81
Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw (2015) 1.52
Ethnicity-dependent polymorphism in Na+-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition. J Biol Chem (2003) 1.44
Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics (2007) 1.39
Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP (2012) 1.32
Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist (2005) 1.21
Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. Cancer Res (2008) 1.20
Anti-angiogenic treatment of gastrointestinal malignancies. Cancer Invest (2005) 1.14
The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res (2006) 1.08
Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos (2005) 1.05
Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study. J Mass Spectrom (2008) 1.00
Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2016) 0.99
A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas. Invest New Drugs (2008) 0.98
Novel mechanistic insights into ectodomain shedding of EGFR Ligands Amphiregulin and TGF-α: impact on gastrointestinal cancers driven by secondary bile acids. Cancer Res (2014) 0.95
A cancer-specific variant of the SLCO1B3 gene encodes a novel human organic anion transporting polypeptide 1B3 (OATP1B3) localized mainly in the cytoplasm of colon and pancreatic cancer cells. Mol Pharm (2012) 0.95
Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors. Clin Cancer Res (2011) 0.95
A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors. Cancer Chemother Pharmacol (2009) 0.95
A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. Mol Endocrinol (2007) 0.94
Inhibitors of the immunoproteasome: current status and future directions. Curr Pharm Des (2013) 0.92
Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. Cancer Chemother Pharmacol (2012) 0.91
Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib. Mol Pharm (2012) 0.91
Novel targets in esophageal and gastric cancer: beyond antiangiogenesis. Expert Opin Investig Drugs (2009) 0.89
A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma. J Cancer Ther (2013) 0.88
Organic anion transporting polypeptide 1B3 (OATP1B3) is overexpressed in colorectal tumors and is a predictor of clinical outcome. Clin Exp Gastroenterol (2008) 0.85
Activity-based near-infrared fluorescent probe for LMP7: a chemical proteomics tool for the immunoproteasome in living cells. Chembiochem (2012) 0.85
Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel. Cancer Chemother Pharmacol (2014) 0.84
Role of hypoxia inducible factor-1α in the regulation of the cancer-specific variant of organic anion transporting polypeptide 1B3 (OATP1B3), in colon and pancreatic cancer. Biochem Pharmacol (2013) 0.84
Revisiting the role of the immunoproteasome in the activation of the canonical NF-κB pathway. Mol Biosyst (2012) 0.83
A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer. Gastrointest Cancer Res (2012) 0.82
A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer. Cancer Chemother Pharmacol (2007) 0.81
Targeted Degradation of Proteins by PROTACs. Curr Protoc Chem Biol (2010) 0.81
Administration of oxaliplatin to a pregnant woman with rectal cancer. Cancer Chemother Pharmacol (2008) 0.80
Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma. Clin Colorectal Cancer (2008) 0.79
A FRET-based approach for identification of proteasome catalytic subunit composition. Mol Biosyst (2014) 0.79
Statistical methods for assays with limits of detection: Serum bile acid as a differentiator between patients with normal colons, adenomas, and colorectal cancer. J Carcinog (2011) 0.78
The epidermal growth factor receptor as a target for gastrointestinal cancer therapy. Curr Treat Options Oncol (2004) 0.78
PSMB9 codon 60 polymorphisms have no impact on the activity of the immunoproteasome catalytic subunit B1i expressed in multiple types of solid cancer. PLoS One (2013) 0.78
Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab. Target Oncol (2014) 0.78
Proteasome inhibitors with pyrazole scaffolds from structure-based virtual screening. J Med Chem (2015) 0.77
The immunoproteasome as a therapeutic target for hematological malignancies. Curr Cancer Drug Targets (2014) 0.77
Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab. Onco Targets Ther (2009) 0.76
A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies. Am J Clin Oncol (2008) 0.76
A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies. Cancer Chemother Pharmacol (2014) 0.75
Elucidating the catalytic subunit composition of distinct proteasome subtypes: a crosslinking approach employing bifunctional activity-based probes. Chembiochem (2014) 0.75
A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma. Int J Radiat Oncol Biol Phys (2007) 0.75
Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer. Invest New Drugs (2008) 0.75
Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors. Eur J Clin Pharmacol (2013) 0.75
A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors. Invest New Drugs (2010) 0.75
A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas. Radiother Oncol (2005) 0.75